Charles Chuah

10.5k citations

108 papers · 4.6k indexed · 3 hit papers · h-index 28

Impact in

Hematology top 0.1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Hematology 99
- Chronic Myeloid Leukemia Treatments 85
- Acute Myeloid Leukemia Research 16
Genetics 71
- Chronic Lymphocytic Leukemia Research 66
- Myeloproliferative Neoplasms: Diagnosis and Treatment 5

Co-authors: Jörge E. Cortes Andreas Hochhaus Hagop M. Kantarjian Michele Baccarani Concepción Boqué Neil P. Shah Jiřı́ Mayer Dong‐Wook Kim
Journals: Blood (32 papers)Journal of Clinical Oncology (16 papers)Leukemia (7 papers)Cancer (3 papers)Oncotarget (3 papers)
Partner nations: Singapore United States Italy

In The Last Decade

Charles Chuah

100 papers receiving 4.5k citations

Hit Papers

align trajectories log scale

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial 2017 · 320 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Journal of Clinical Oncology
2016 Journal of Clinical Oncology
2010 New England Journal of Medicine

Peers

Countries citing papers authored by Charles Chuah

Since Specialization

Citations

This map shows the geographic impact of Charles Chuah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Chuah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Chuah more than expected).

Fields of papers citing papers by Charles Chuah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Chuah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Chuah. The network helps show where Charles Chuah may publish in the future.

Co-authors

The 25 scholars most cited alongside Charles Chuah, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Charles Chuah Line = papers co-authored together Charles Chuah links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies Leukemia ·Stephen Jun Fei Chong, Carol Booker, Kartini Iskandar, Kazufumi Ohnishi, Chuqi Wang, Yuhan Wang, Romain Guièze, Е. Ромахова, Ratana Lim, Catherine J. Wu, Wee Joo Chng, Alice M.S. Cheung, Charles Chuah, Matthew S. Davids, Shazib Pervaiz	2025	2
2	Revolutionising Cardio-Oncology Care with Precision Genomics International Journal of Molecular Sciences ·Jun Hua Chong, Charles Chuah, Caroline Lee	2025	2
3	Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC. Journal of Clinical Oncology ·Michael W. Deininger, Jane Apperley, Christopher Arthur, Charles Chuah, Andreas Hochhaus, Hugues de Lavallade, Jeffrey H. Lipton, Elza Lomaia, James McCloskey, Lori J. Maness, Michael J. Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, T Goo, Xiaowei Ren, Alexander Vorog, Hagop M. Kantarjian, Jörge E. Cortes	2024	0
4	The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies Leukemia ·Iqbal Husain Thaker, Kristof Mory, Vaidehi Krishnan, Ankit Dabi, King Pan Ng, Chuqi Wang, Shruti Bhatt, Charles Chuah, David E. Bergstrom, S. Tiong Ong	2024	0
5	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial Leukemia ·Tim H. Brümmendorf, Jörge E. Cortes, Dragana Milojković, Carlo Gambacorti‐Passerini, Richard E. Clark, Philipp le Coutre, Valentín García‐Gutiérrez, Charles Chuah, Vamsi Kota, Jeffrey H. Lipton, Philippe Rousselot, Michael J. Mauro, Andreas Hochhaus, Benjamin Hanks, Eric Leip, Кошевой Александр Петрович, N. Hassan, Andrea Viqueira, Michael W. Deininger, (unknown)	2022	79
6	Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells Molecular Cancer Therapeutics ·Ege Sezen, Zhiyong Ye, Alice M.S. Cheung, Yufen Goh, Hsueh Ling Janice Oh, Ravisankar Rajarethinam, Siok Ping Yeo, Wenzhong Lan, Esther Hian Li Chan, Lip Kun Tan, Soo‐Yong Tan, Charles Chuah, Wee Joo Chng, John E. Connolly, 변태호	2021	37
7	SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia Leukemia ·Roberto dos Santos Rondon, Kian Leong Lee, Shanshan Cheng, Jia Li, Iqbal Husain Thaker, Margot J. Wagenmakers, Clara Chong Hui Ong, Huihua Li, Hein Than, Olga Anczuków, Adrian R. Krainer, Xavier Roca, Steve Rozen, Jabed Iqbal, Henry Yang, Charles Chuah, S. Tiong Ong	2020	21
8	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia Leukemia ·Susan Branford, Dennis Dong Hwan Kim, Jane F. Apperley, Christopher A. Eide, Satu Mustjoki, S. Tiong Ong, Georgios Nteliopoulos, Thomas Ernst, Charles Chuah, Carlo Gambacorti‐Passerini, Michael J. Mauro, Brian Druker, Dong‐Wook Kim, François‐Xavier Mahon, Jörge E. Cortes, Jerry Radich, Andreas Hochhaus, Timothy P. Hughes	2019	84
9	Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia Journal of Cancer Research and Clinical Oncology ·(unknown), Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah, Dong‐Wook Kim, Dragana Milojković, Philipp le Coutre, Valentín García‐Gutiérrez, Rocco J. Crescenzo, Carla Mamolo, Arlene Reisman, Andreas Hochhaus, Tim H. Brümmendorf	2019	15
10	The arginase inhibitor Nω−hydroxy−nor−arginine (nor−NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target PLoS ONE ·King Pan Ng, A. L. Danilyuk, S I Pahomov, Antoine A. Puech, wafaa Abdel rahman, Jochen Winkelmann, Е.А. Свердликова, Kian Leong Lee, Charles Chuah, Toshio Suda, S. Tiong Ong	2018	11
11	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial Journal of Clinical Oncology ·Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian, Michele Baccarani, Jiřı́ Mayer, Concepción Boqué, Neil P. Shah, Charles Chuah, Luís Casanova, Elena Kurbatova, George Manos, Andreas Hochhaus Hit paper breakdown →	2016	621
12	High-throughput genotyping of CRISPR/Cas9-mediated mutants using fluorescent PCR-capillary gel electrophoresis Scientific Reports ·Muhammad Khairul Ramlee, Tingdong Yan, Alice M.S. Cheung, Charles Chuah, Shang Li	2015	70
13	Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia Experimental Hematology ·Mahbube Fadaei, Wei Xiang, Bee Ling Ng, Penadés Casanova, Ralph M. Bunte, Patrick J. Casey, Mei Wang, Charles Chuah	2015	11
14	A novel Bcr-Abl–mTOR–eIF4A axis regulates IRES-mediated translation of LEF-1 Open Biology ·Becky Pinjou Tsai, Judith Jiménez, Sharon Lim, Kerry Fitzgerald, Min Zhang, Charles Chuah, Jorge Luis Ilquimiche Melly, José Luis Doval Lorente, S. Tiong Ong, Bert L. Semler, Marian L. Waterman	2014	22
15	Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056) Blood ·Jörge E. Cortes, Giuseppe Saglio, Michele Baccarani, Hagop M. Kantarjian, Jiřı́ Mayer, Concepción Boqué, Neil P. Shah, Charles Chuah, Luís Casanova, Geetha Narayanan, Elena Kurbatova, George Manos, Andreas Hochhaus	2014	59
16	Bilineal T lymphoblastic and myeloid blast transformation in chronic myeloid leukemia with TP53 mutation—an uncommon presentation in adults Current Oncology ·Suren Krishnan, たみこ松井, Charles Chuah, Soo‐Yong Tan	2013	3
17	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation Blood ·Jörge E. Cortes, Jeff H. Lipton, Delphine Réa, Raghunadharao Digumarti, Charles Chuah, Nisha Nanda, F Scheer, Adam R. Craig, Mauricette Michallet, Franck E. Nicolini, Hagop M. Kantarjian	2012	89
18	Regulation of myeloid leukaemia by the cell-fate determinant Musashi Nature ·Takahiro Ito, Hyog Young Kwon, Bryan Zimdahl, Kendra L. Congdon, Jordan Blum, William Lento, Chen Zhao, Anand S. Lagoo, Gareth Gerrard, Letizia Foroni, John M. Goldman, Imrotus Solikhah, Soo Hyun Kim, Dong‐Wook Kim, Charles Chuah, Vivian G. Oehler, Jerald P. Radich, Craig T. Jordan, Tannishtha Reya	2010	272
19	Dual inhibition of ras and bcr‐abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission British Journal of Haematology ·Jiří Pavlů, R. Trapani, Charles Chuah, Jaspal Kaeda, John M. Goldman, Jane F. Apperley, David Marín	2007	8
20	Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells Leukemia ·Charles Chuah, David Barnes, Marwan Kwok, A. Corbin, Michael W. Deininger, Brian Druker, J V Melo	2005	42

About Charles Chuah

Charles Chuah is a scholar working on Hematology, Genetics, Rheumatology, Public Health, Environmental and Occupational Health and Business and International Management, having authored 108 papers that have together received 4.6k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (85 papers), Chronic Lymphocytic Leukemia Research (66 papers), Acute Lymphoblastic Leukemia research (22 papers), Eosinophilic Disorders and Syndromes (21 papers), Acute Myeloid Leukemia Research (16 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Protein Degradation and Inhibitors (7 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). The work is most often cited by research in Hematology (3.5k citations), Genetics (2.7k citations), Rheumatology (1.6k citations), Oncology (860 citations) and Pathology and Forensic Medicine (309 citations). Charles Chuah has collaborated with scholars based in Singapore, United States and Italy. Frequent co-authors include Jörge E. Cortes, Andreas Hochhaus, Hagop M. Kantarjian, Michele Baccarani, Concepción Boqué, Neil P. Shah, Jiřı́ Mayer, Dong‐Wook Kim, Giuseppe Saglio and M. Brigid Bradley‐Garelik. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Cancer and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact